Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 6.27%
As of Wednesday, September 16, Minerva Neurosciences, Inc.’s NERV share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Commentary & Analysis
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 6.73%
As of Tuesday, September 15, Minerva Neurosciences, Inc.’s NERV share price has dipped by 6.73%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 6.03%
As of Tuesday, August 25, Minerva Neurosciences, Inc.’s NERV share price has surged by 6.03%, which has investors questioning if this is right time to sell.Michael Rose
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 5.01%
As of Friday, August 21, Minerva Neurosciences, Inc.’s NERV share price has surged by 5.01%, which has investors questioning if this is right time to sell.Michael Rose
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 8.59%
As of Wednesday, August 19, Minerva Neurosciences, Inc.’s NERV share price has surged by 8.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | NERV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $162.3 | $257.9 | 26% |
|
| Shares Out (Mil) | 79.1 | 54.3 | 57% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 34.3 | 41.4 | 39% |
|
| Beta | -0.10 | 0.95 | 4% |
|
| Avg Daily Volume (000s) | 233 | 674 | 45% |
|
| Price Change (52-week) |
55.3% | 51.5% | 85% |
|
| Growth | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (174.7%) | (10.1%) | 0% |
|
| EPS (5yr) | (147.7%) | 15.8% | 0 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.4% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.180) | ($0.570) | ($0.420) | |
| Month Ago EPS | na | ($0.570) | ($0.420) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.010) | ($0.200) | na | |
| Year/Year Chg | 30.4% | (98.4%) | (99.6%) | |
| Financials | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($394) | ($43) | 4% |
|
| EPS (TTM) | ($14.441) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($26) | ($32) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $171 | $174 | 25% |
|
| Valuation | NERV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NERV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (628.4%) | (47.7%) | 0% |
|
| ROE | 321.4% | (54.9%) | 99% |
|
| Liabilities to Assets | 312.0% | 29.1% | 100% |
|
| F-Score | 2 | 3 | na |
|
Minerva Neurosciences, Inc. did not pass any screens on 9/25/2026.
